不可切除III期非小细胞肺癌的免疫治疗:现状与新型治疗策略
不可切除III期非小细胞肺癌的标准治疗为同步放化疗后1年辅助度伐利尤单抗,但5年无病生存仅约1/3。本综述汇总该领域临床试验结果,讨论不同免疫治疗时机(同步放化疗后、序贯放化疗后巩固、诱导、同步及序贯)的生物学依据、 pitfalls 与潜在获益,并探讨预测生物标志物等未满足需求。
要点
- 不可切除III期NSCLC标准治疗为同步放化疗后1年辅助度伐利尤单抗,5年无病生存仅1/3。
- 新型策略包括同步放化疗后不同抗PD-(L)1抗体、序贯放化疗后巩固免疫、诱导免疫及同步免疫。
- 跨试验比较因免疫治疗时机及入排标准不同而具有挑战性。
核心结论
- 不可切除III期NSCLC标准治疗为同步放化疗后1年辅助度伐利尤单抗,但仅1/3患者5年时存活且无病。
- 多种新型免疫治疗策略正在开发以改善该人群结局。
- 跨试验比较因免疫治疗时机和入排标准不同而具有挑战性。
- 识别不同患者亚群以定制抗癌治疗是优先事项,尤其对于III期NSCLC这类异质性疾病。
研究设计与样本
- 综述,汇总研究不可切除III期NSCLC免疫治疗的临床试验结果。
- 讨论生物学依据、 pitfalls 与潜在获益,重点关注化疗、放疗与不同单克隆抗体间的协同机制及其对肿瘤免疫微环境的影响。
- 讨论正在进行的临床试验的设计与所解决的问题。
主要发现
- 同步放化疗后1年辅助度伐利尤单抗虽带来生存获益,但5年时仅1/3患者存活且无病。
- 正在开发的策略包括同步放化疗后不同抗PD-(L)1抗体、序贯放化疗后巩固免疫治疗、同步放化疗前诱导免疫治疗以及同步放化疗和/或序贯放化疗期间同步免疫治疗。
- 跨试验比较因免疫治疗时机不同及患者入排标准不同而尤为困难。
关键数值与推荐
- 标准治疗:同步放化疗后1年辅助度伐利尤单抗。
- 5年时存活且无病者仅1/3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 跨试验比较因免疫治疗给药时机不同及患者入排标准不同而尤为困难。
- 需要预测性生物标志物(如影像组学和循环肿瘤DNA)等开放问题与未满足的临床需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The standard of care for patients with stage III non-small-cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT) followed by 1 year of adjuvant durvalumab. Despite the survival benefit granted by immunotherapy in this setting, only 1/3 of patients are alive and disease free at 5 years. Novel treatment strategies are under development to improve patient outcomes in this setting: different anti-programmed cell death protein 1/programmed death-ligand 1 [anti-PD-(L)1] antibodies after CCRT, consolidation immunotherapy after sequential chemoradiotherapy, induction immunotherapy before CCRT and immunotherapy concurrent with CCRT and/or sequential chemoradiotherapy. Cross-trial comparison is particularly challenging in this setting due to the different timing of immunotherapy delivery and different patients' inclusion and exclusion criteria. In this review, we present the results of clinical trials investigating immune therapy in unresectable stage III NSCLC and discuss in-depth their biological rationale, their pitfalls and potential benefits. Particular emphasis is placed on the potential mechanisms of synergism between chemotherapy, radiation therapy and different monoclonal antibodies, and how this affects the tumor immune microenvironment. The designs and questions tackled by ongoing clinical trials are also discussed. Last, we address open questions and unmet clinical needs, such as the necessity for predictive biomarkers (e.g. radiomics and circulating tumor DNA). Identifying distinct subsets of patients to tailor anticancer treatment is a priority, especially in a heterogeneous disease such as stage III NSCLC.
引用
- Cortiula F, Reymen B, Peters S, et al. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches. Ann Oncol. 2022. PMID: 35777706. doi:10.1016/j.annonc.2022.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。